

Joint Press Release

WADA-JADA-FPMAJ Cooperation to Advance the Fight against Doping in Sport

26 June 2013

The World Anti-Doping Agency (WADA), the Japan Anti-Doping Agency (JADA) and the Federation of Pharmaceutical Manufacturers' Association of Japan (FPMAJ) signed a Joint Declaration on Cooperation in the Promotion of Anti-Doping Activity & Development of Integrity of Sport for the promotion of anti-doping activity and development of integrity of sport in Tokyo, Japan earlier today.

The Declaration was signed by Mr. Kazuhiro Hayashi, Director of WADA Asia/Oceania Regional Office, Prof. Hidenori Suzuki, President of JADA and Mr. Haruo Naito, President of the FPMAJ. Also in attendance were Mr. Teru Fukui, Minister in charge of Sports & WADA Executive Committee member and Dr. Ichiro Kono, President of the Japan Sport Council.



From left to right: Prof. Hidenori Suzuki, President of JADA; Mr. Haruo Naito, President of FPMAJ; Mr. Kazuhiro Hayashi, Director of WADA Asia/Oceania Regional Office.

Mr. David Howman, Director General of WADA, sent a video message to welcome the cooperation, and highlighted the importance of the agreement. "We are very pleased that JADA and FPMAJ have agreed to this cooperation at what is an important time in the fight against doping in sport," said Howman.

"A crucial part of WADA's strategy is to develop partnerships with organizations that have the expertise to identify medicinal substances that could be of interest to dopers. This, in turn, will help facilitate much faster development of detection



methods in the context of doping in sport. We see this as a win-win collaboration, and we look forward to a long, successful relationship," he added.

Mr. Teru Fukui, Minister in charge of Sports and WADA Executive Committee member, attended the signage meeting and sent the government's strong support to the partnership between WADA, JADA and FPMAJ. He stressed: "I am delighted to see this partnership developed and I would like to send my gratitude to all three partners for their commitment to the global development of anti-doping activity through this Joint Declaration."

The Declaration aims for JADA, WADA and FPMAJ to share the recognition that doping is both a public health and significant societal issue. It is hoped the agreement will help develop the integrity of sport by allowing member associations and companies of FPMAJ to cooperate with WADA and JADA.

The cooperation aims to convey information regarding medicines with possible doping potential, identify potential doping compounds at an early stage of clinical trials and develop research projects on detection under a confidentiality agreement amongst the parties' volunteer bases. In cooperation with WADA, JADA effectively promotes and provides the latest information on anti-doping for stakeholders.

In echoing David Howman's words, Prof. Suzuki said: "We are very happy to see the joint effort achieved with WADA and FPMAJ, with our stronger commitment in the protection and development of the spirit of sport. Recognising doping as a public health

issue, we hope to establish a collaborative partnership with WADA and FPMAJ by sharing information effectively. We wish to ensure that this joint declaration will create a sporting environment where we can respect sport integrity across society.”

Mr. Naito commented: “Our mission as the pharmaceutical industry is to create hope for patients and consumers through the provision of medicines. We feel a great sense of regret that medicines developed to benefit patients could potentially be used for doping, and also recognize that this a public health issue. We believe that by using the information and analytical methods we have available we can play a vital role in the prevention of such misuse. The pharmaceutical industry will help promote anti-doping activity through this new collaborative partnership between the FPMAJ, WADA and JADA.”

In July 2010, WADA and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), of which President was Mr. Haruo Naito at the time, signed the Joint Declaration on Cooperation in the Fight against Doping in Sport. Since the Declaration, WADA has developed partnerships with the pharmaceutical and biotechnology industries, which will provide expertise in finding solutions on doping and eradicating drug abuse.

WADA strongly supports further cooperation between JADA and the Pharmaceutical Industry in Japan, and expects the new cooperation to promote and broaden an early warning system practiced in successful bilateral collaborative exercises between WADA and individual pharmaceutical companies at both national and regional levels.



About WADA

The World Anti-Doping Agency (WADA) is the international independent organization created in 1999 to promote, coordinate and monitor the fight against doping in sport in all its forms. The Agency is composed and funded equally by the sports movement and governments of the world. Its key activities include scientific research, education, development of anti-doping capacities and monitoring of the World Anti-Doping Code – the first document harmonizing regulations regarding anti-doping in all sports and all countries.

<http://www.wada-ama.org/>

About JADA

The Japan Anti-Doping Agency (JADA) was founded in 2001 as the cooperative effort of all stakeholders in Japan. Supported by the Ministry of Education, Culture, Sports, Science and Technology (MEXT), JADA endeavours to lead the anti-doping activity with its key activity areas of education, awareness raising, research, doping control and the JADA Sports Pharmacist Program. It strives to promote and strengthened a value-based education program in Japan in view of development of people and society through sport.

<http://www.playtruejapan.org/>

About FPMAJ

The Federation of Pharmaceutical Manufacturers' Associations of JAPAN (FPMAJ) is the only umbrella organisation for all pharmaceutical industry in Japan and contributes the integrity of pharmaceutical industry and the health of citizen. FPMAJ is composed of 14 Pharmaceutical Industry Associations including JPMA (Japan Pharmaceutical Manufacturers Association) and other specific pharmaceutical industry associations such as Home medicine, OCT, Generic drugs and others mainly at national level and 17 Regional (Prefectural) Associations covering almost over Japan. Their main activities include examination on the common issues of the pharmaceutical industry, proposal on the policies to the related authorities, improvement of the quality of medicines, raw material, standard, production, distribution and promotion of international cooperation. Recently FPMAJ is growing their interest and commitment to the public health concern, the misuse problems of their products and the fight against doping in sport effectively.

<http://www.fpmaj.gr.jp/>

**JOINT DECLARATION ON COOPERATION IN THE PROMOTION OF ANTI-DOPING
ACTIVITY &
DEVELOPMENT OF INTEGRITY OF SPORT**

**Japan Anti-Doping Agency, World Anti-Doping Agency &
The Federation of Pharmaceutical Manufacturers' Associations of JAPAN**

Preamble

Doping in sport is against the spirit of fair play and brings the unfair advantage to the fair competition in sport and also causes the significant risk in health of the doped athletes. These threats today can affect not only among the elite athletes but also among students and amateur and occasional athletes.

Anti-Doping activity is to respect the fundamental core value of sport and it is essential to flourish the real sporting activity under the universally agreed principle. Moreover, those enriched values flourished through sporting activity are common values and principles in society. In view of this, doping is considered as a public health issue.

It has become imperative to prevent the abuse and misuse of sport-related drugs and to establish a collaborative relationship between the international and national governmental and non-governmental agencies for their mutual benefit.

Therefore, the collaborative efforts between a pharmaceutical agency and an anti-doping agency is aspired regarding the prevention in the risk of misuse of medicines with doping potential and identify potential doping compounds at an early stage of clinical trials, as well as the development of research in detection methods. In July 2010, the World Anti-Doping Agency (WADA) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) signed "Joint Declaration on Cooperation in the Fight against Doping in Sport" (Japan Pharmaceutical Manufacturers Association (JPMA) under The Federation of Pharmaceutical Manufacturers' Associations of JAPAN (FPMAJ) is a major member association of IFPMA).

Scope

The Japan Anti-Doping Agency (JADA) strives to develop people and society through sport and to protect and develop the core value of sport that essentially celebrates the human potential reached. In close collaboration with WADA, the government, sport movement and all stakeholders, JADA endeavours to lead anti-doping activity in order to foster a society where the real champion is valued.

The Federation of Pharmaceutical Manufacturers' Associations of JAPAN (FPMAJ) is the umbrella organisation for all pharmaceutical industry in Japan and contributes the integrity of pharmaceutical industry and the health of citizen. Therefore, FPMAJ is committed to support the development of anti-doping activity.

The World Anti-Doping Agency (WADA) supports this collaboration and cooperation between JADA and FPMAJ to effectively promote the anti-doping activity.

Objective

JADA, WADA and FPMAJ share the recognition that doping is a public health issue and a significant societal issue. They contribute to the development of integrity of sport through the cooperation against doping.

Those member associations and companies of FPMAJ participate in this collaboration through providing information on the prescription or non-prescription drug with doping potential and on detection technology to prevent abuse of doping compounds under development on their volunteer bases. They cooperate with JADA and WADA as followings:

1. Those member associations and companies of FPMAJ, except those of the members of The Japan Pharmaceutical Manufacturers Association (JPMA) and already have or wish to have collaboration or agreement directly with WADA, convey information only via a contact person designated by the parties regarding the medicines with the possible doping potential and identify potential doping compounds at an early stage of clinical trials, as well as the development of research in detection methods. Protection of any proprietary or confidential information will be achieved by means of a confidentiality agreement and not shared with any third parties, unless mutually agreed in writing. Based on the confidentiality principle, JADA shares the information with WADA.
2. To develop anti-doping activity as part of public health matter, JADA in cooperation with WADA effectively promotes and provides the latest information on anti-doping not only to elite athletes and their entourage but also to those specialised in pharmacology and those engaged in the development of medicines as well as to the researcher engaged in the development of analytical methods. FPMAJ and its member associations support and cooperate with these activities.

Herein, WADA, JADA and FPMAJ declare to establish the collaborative relations to the promotion of anti-doping and flourish the spirit and core value of sport.

This Declaration enters immediately into force upon signature by the representatives of these three organisations, below: